Pruritis
Drug research and approvals for pruritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 59 studies of pruritis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 16 drug trials for it since 2013.
- Recruiting worldwide: 59
- Trials authorized in Canada: 16
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting now
Newest posted first, of 59 recruiting on ClinicalTrials.gov ↗- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNCT07916480 · Phase 3 · Arcutis Biotherapeutics, Inc. · starts Oct 30, 2026
- Observational Analytical Validation Study of the Replior ScratchSenseNCT07909967 · Not reported · Replior AB · starts Oct 12, 2026
- In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates…NCT07898475 · Not reported · Dr. Amara Safdar · starts Oct 2, 2026
- Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque PsoriasisNCT07844772 · Not reported · Istanbul Training and Research Hospital · starts Jun 11, 2026
- A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic…NCT07811869 · Phase 3 · Novartis Pharmaceuticals · starts Oct 7, 2026
- A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic…NCT07700056 · Phase 3 · Novartis Pharmaceuticals · starts Aug 24, 2026
- A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by DermatophytesNCT07668999 · Phase 1 · Sinomune Pharmaceutical Co., Ltd · starts Jul 21, 2026
- tDCS for Reducing the Incidence of OEI After Cesarean SectionNCT07569783 · Not applicable · Affiliated Hospital of Nantong University · starts May 10, 2026
- Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis…NCT07560618 · Phase 4 · Integrative Skin Science and Research · starts Jul 21, 2026
How its trials ended
304 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 68 whose ending is known, 49% met their primary endpoint, 7% missed it and 44% stopped early.
- Completed, result not reported16053%
- Ongoing4414%
- Met its primary endpoint3311%
- Status unknown3211%
- Stopped: other or unclear176%
- Missed its primary endpoint52%
- Stopped: enrollment or feasibility52%
- Stopped: lack of efficacy31%
- Stopped: sponsor or business decision31%
- Stopped: safety1<1%
- Stopped: funding1<1%
Trials authorized in Canada
The 10 newest of 16; search them all in Canada trials| Jul 9, 2026 | A 52-week multi-center, randomized, double-blind, placebo controlled phase 3 study to evaluate the efficacy, safety and tolerability of remibrutinib in adult…Remibrutinib (LOU064) | Novartis Pharmaceuticals | Pending |
| Jul 9, 2026 | A 52-week multi-center, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy, safety and tolerability of remibrutinib in adult…Remibrutinib (LOU064) | Novartis Pharmaceuticals | Pending |
| Mar 9, 2026 | An exploratory proof of concept study to assess the pharmacokinetics/pharmacodynamics of nemolizumab (CD14152) in adult participants with chronic pruritus of…Nemolizumab (CD14152) | Galderma Canada Inc | Closed |
| Feb 27, 2026 | Incidence of pruritus using intrathecal fentanyl versus epidural fentanyl to initiate labour analgesiaFentanyl | Dr. Valérie Zaphiratos | Pending |
| Oct 25, 2024 | A phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus…Dupixent | Sanofi-Aventis Canada Inc | Ongoing |
| Sep 13, 2023 | A multicenter, randomized, double-blind, placebo-controlled 12-week study to evaluate the pharmacokinetics, pharmacodynamics, and safety of oral difelikefalin…Difelikefalin | Cara Therapeutics | Closed |
| Dec 7, 2021 | ¿master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in…Dupilumab (SAR231893/REGN668) | Sanofi-Aventis Canada Inc | Ongoing |
| Nov 9, 2021 | Dialysis symptom control-pruritus outcome trial (disco-pot): a randomized blinded placebo controlled crossover trialNabilone | University of Manitoba | Closed |
| Dec 16, 2020 | A randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of oral difelikefalin (CR845) for moderate to severe…Difelikefalin (CR845) | Cara Therapeutics | Closed |
| May 15, 2020 | Long-term safety and tolerability study of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis.Linerixibat (GSK2330672) | GSK | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA